You are here

Targeting B-cell lymphoma with Leukothera-phase II

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42CA173900-02
Agency Tracking Number: R42CA173900
Amount: $1,939,262.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-26
Award End Date (Contract End Date): 2017-08-31
Small Business Information
15 PELHAM RD
Kendall Park, NJ 08824-1309
United States
DUNS: 829616676
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BENJAMIN BELINKA
 (732) 371-2694
 benbelinka@actinobac.com
Business Contact
 BENJAMIN BELINKA
Phone: (732) 371-2694
Email: benbelinka@actinobac.com
Research Institution
 RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS
 
83 SOMERSET ST
NEW BRUNSWICK, NJ 08901-1281
United States

 Nonprofit college or university
Abstract

DESCRIPTION provided by applicant B cell lymphoma is cancer of B lymphocytes and accounts for more than deaths in the U S each year While many patients respond to currently available therapy there is a high rate of cancer relapse and inability for the patients o tolerate chemotherapy Thus there is a significant need to make available to these patients newer therapies that are more effective and better tolerated than the drugs that are currently used Actinobac Biomed Inc is developing a natural biologic therapy that seeks out and kills a subset of white blood cells WBCs This therapy Leukothera R LtxA leukotoxin is a native protein derived from an oral bacterium LtxA binds specifically to the active form of lymphocyte function associated antigen LFA and causes cell death LFA is found exclusively on WBCs and malignant WBCs overexpress the molecule making them ideal targets for the drug During the phase I stage of this STTR application we showed that LtxA kills malignant B cells using a unique mechanism of action which involves Fas death receptor and caspase lymph node tissue samples from B cell lymphoma patients express high levels of LFA LtxA causes complete regression of tumors in a humanized mouse model for B cell lymphoma and results in long term survival the drug is well tolerated highly active and does not cause a neutralizing immune response in healthy dogs or a dog with naturally occurring lymphoma and we have initiated expression and production of recombinant LtxA in a cGMP drug manufacturing facility in preparation for Investigational New Drug IND enabling studies and clinical trials Important pharmaceutical properties of LtxA include the drug works rapidly in vivo within minutes or less doses as low as g kg have been shown to be highly active in animals neutralizing antibody to LtxA is not generated in healthy or diseased animals even after repeat dosing and the high specificity of the drug allows targeting of a subset of WBCs and complete depletion of WBCs has never been observed with LtxA treatment During this STTR phase II proposal Actinobac will carry out IND enabling studies that will be included in the IND application to the FDA PUBLIC HEALTH RELEVANCE B cell lymphomas kill thousands of people each year We are developing a biotherapeutic agent Leukothera R that has targeted specificity for malignant white blood cells This phase II application will accomplish studies that are required for FDA approval to start testing in human patients with B cell lymphoma

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government